

# **SAFETY DATA SHEET**

## 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

Synonyms CARDISURE FLAVOURED TABLETS ● PIMOCARD ● PIMOSURE

1.2 Uses and uses advised against

Uses VETERINARY USE

FOR THE TREATMENT OF CANINE CONGESTIVE HEART FAILURE ORIGINATING FROM VALVULAR INSUFFICIENCY (MITRAL AND/OR TRICUSPID REGURGITATION) OR DILATED CARDIOMYOPATHY.

Uses advised against Not for human use.

1.3 Details of the supplier of the product

Supplier name DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY LTD

Address 2 Cal Close, Somersby, NSW, 2250, AUSTRALIA

**Telephone** 1300 015 825; (02) 4372 1661

Fax (02) 4372 1668

Email info.au@dechra.com

Website http://www.dechra.com.au/

1.4 Emergency telephone numbers

**Emergency** 13 11 26 (Poisons Information Centre)

# 2. HAZARDS IDENTIFICATION

#### 2.1 Classification of the substance or mixture

CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

**Physical Hazards** 

Not classified as a Physical Hazard

**Health Hazards** 

Specific Target Organ Toxicity (Single Exposure): Category 3 (Respiratory Irritation)

**Environmental Hazards** 

Not classified as an Environmental Hazard

2.2 GHS Label elements

Signal word WARNING

**Pictograms** 



**Hazard statements** 

H335 May cause respiratory irritation.

**Prevention statements** 

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.

Page 1 of 6



SDS Date: 21 Sep 2021

# PRODUCT NAME CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

Response statements

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P312 Call a POISON CENTRE or doctor/physician if you feel unwell.

Storage statements

P403 + P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

**Disposal statements** 

P501 Dispose of contents/container in accordance with relevant regulations.

#### 2.3 Other hazards

Please note that respiratory irritation is unlikely to occur due to physical form of the product (tablet) and how it is packaged.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

## 3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
CELLULOSE	9004-34-6	232-674-9	60 to 70%
PIMOBENDAN	74150-27-9	-	0.6%
ADDITIVE(S)	-	-	Remainder

## 4. FIRST AID MEASURES

## 4.1 Description of first aid measures

Eye If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to

stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

**Inhalation** If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

**Skin** If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

Ingestion For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If

swallowed, do not induce vomiting.

First aid facilities None allocated.

## 4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

#### 4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

# 5. FIRE FIGHTING MEASURES

# 5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

# 5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve carbon oxides and hydrocarbons when heated to decomposition.

# 5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

Page 2 of 6

#### 5.4 Hazchem code

None allocated.

#### 6. ACCIDENTAL RELEASE MEASURES



SDS Date: 21 Sep 2021

# PRODUCT NAME CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

#### 6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

#### 6.2 Environmental precautions

Prevent product from entering drains and waterways.

#### 6.3 Methods of cleaning up

If spilt, collect and reuse where possible.

#### 6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

# 7. HANDLING AND STORAGE

# 7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 25°C. Do not expose to elevated temperatures above 30°C for long periods.

## 7.3 Specific end uses

No information provided.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### 8.1 Control parameters

#### **Exposure standards**

Ingredient	Reference	TWA		STEL	
mgredient		ppm	mg/m³	ppm	mg/m³
Cellulose (paper fibre) (a)	SWA [AUS]		10		

Page 3 of 6

## **Biological limits**

No biological limit values have been entered for this product.

## 8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

PPE

**Eve / Face** Not required under normal conditions of use.

**Hands** Individuals with sensitive skin should consider wearing latex gloves.

**INSOLUBLE** 

**Body** Not required under normal conditions of use. **Respiratory** Not required under normal conditions of use.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

# 9.1 Information on basic physical and chemical properties

**Appearance** LIGHT BROWN ROUND TABLET Odour **ODOURLESS Flammability** NON FLAMMABLE Flash point NOT RELEVANT **Boiling point** NOT AVAILABLE **Melting point** NOT AVAILABLE **Evaporation rate** NOT AVAILABLE **NOT AVAILABLE** pН **NOT AVAILABLE** Vapour density NOT AVAILABLE Relative density

ChemAlert.

Solubility (water)

SDS Date: 21 Sep 2021

# PRODUCT NAME CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

## 9.1 Information on basic physical and chemical properties

Vapour pressure **NOT AVAILABLE** NOT RELEVANT Upper explosion limit Lower explosion limit NOT RELEVANT Partition coefficient NOT AVAILABLE **NOT AVAILABLE** Autoignition temperature **NOT AVAILABLE Decomposition temperature Viscosity NOT AVAILABLE Explosive properties NOT AVAILABLE Oxidising properties NOT AVAILABLE Odour threshold NOT AVAILABLE** 

### 10. STABILITY AND REACTIVITY

## 10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

#### 10.2 Chemical stability

Stable under recommended conditions of storage.

### 10.3 Possibility of hazardous reactions

Polymerization will not occur.

## 10.4 Conditions to avoid

Avoid contact with incompatible substances.

#### 10.5 Incompatible materials

Compatible with most commonly used materials.

#### 10.6 Hazardous decomposition products

May evolve carbon oxides and hydrocarbons when heated to decomposition.

## 11. TOXICOLOGICAL INFORMATION

## 11.1 Information on toxicological effects

Acute toxicity This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin

contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
CELLULOSE	> 5000 mg/kg (rat)	> 2000 mg/kg (rabbit)	> 5800 mg/m³/4 hours (rat)

**Skin** Contact may result in irritation, redness and rash.

Eye Contact may result in irritation, lacrimation, pain, redness and conjunctivitis.

**Sensitisation** Not classified as causing skin or respiratory sensitisation.

MutagenicityNot classified as a mutagen.CarcinogenicityNot classified as a carcinogen.ReproductiveNot classified as a reproductive toxin.

STOT - single Over exposure may result in irritation of the nose and throat, with coughing. However, due to product form

Page 4 of 6

**exposure** (i.e. tablet), the potential for over exposure is minimised.

STOT - repeated

exposure

Not classified as causing organ damage from repeated exposure.

**Aspiration** Not classified as causing aspiration.

## 12. ECOLOGICAL INFORMATION



SDS Date: 21 Sep 2021

#### PRODUCT NAME CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

### 12.1 Toxicity

This product is not known to be hazardous to the environment.

#### 12.2 Persistence and degradability

No information provided.

## 12.3 Bioaccumulative potential

No information provided.

## 12.4 Mobility in soil

No information provided.

#### 12.5 Other adverse effects

No information provided.

# 13. DISPOSAL CONSIDERATIONS

#### 13.1 Waste treatment methods

For small quantities, collect and place in sealable containers. Dispose of, as with other clinical waste, by high Waste disposal

temperature incineration (recommended > 1100°C). Burial to landfill may be acceptable, but only at an

approved and licensed waste disposal site.

Legislation Dispose of in accordance with relevant local legislation.

# 14. TRANSPORT INFORMATION

#### NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE, IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

## 14.5 Environmental hazards

Not a Marine Pollutant.

# 14.6 Special precautions for user

Hazchem code None allocated.

### 15. REGULATORY INFORMATION

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Poison schedule Classified as a Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

**APVMA Numbers** 81942 (5 MG) • 81944 (10 MG) • 81946 (2.5 MG) • 81948 (1.25 MG)

Classifications Safe Work Australia criteria is based on the Globally Harmonised System (GHS) of Classification and

Page 5 of 6

Labelling of Chemicals (GHS Revision 7).

**AUSTRALIA: AIIC (Australian Inventory of Industrial Chemicals) Inventory listings** 

All components are listed on AIIC, or are exempt.

# 16. OTHER INFORMATION

Additional information



SDS Date: 21 Sep 2021

#### PRODUCT NAME

# CARDISURE FLAVOURED TABLETS (CONTAINING 1.25MG, 2.5MG, 5MG OR 10MG PIMOBENDAN)

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

## PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

#### HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

#### **Abbreviations**

ACGIH American Conference of Governmental Industrial Hygienists

CAS # Chemical Abstract Service number - used to uniquely identify chemical compounds

CNS Central Nervous System

EC No. EC No - European Community Number

EMS Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous

Goods)

GHS Globally Harmonized System

GTEPG Group Text Emergency Procedure Guide IARC International Agency for Research on Cancer

LC50 Lethal Concentration, 50% / Median Lethal Concentration

LD50 Lethal Dose, 50% / Median Lethal Dose

mg/m³ Milligrams per Cubic Metre
OEL Occupational Exposure Limit

pH relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly

alkaline).

ppm Parts Per Million

STEL Short-Term Exposure Limit

STOT-RE Specific target organ toxicity (repeated exposure)
STOT-SE Specific target organ toxicity (single exposure)

SUSMP Standard for the Uniform Scheduling of Medicines and Poisons

SWA Safe Work Australia
TLV Threshold Limit Value
TWA Time Weighted Average

## Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

### Prepared by

Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711 Fax: +61 8 9322 1794

Email: info@rmt.com.au Web: www.rmtglobal.com

[ End of SDS ]



SDS Date: 21 Sep 2021 Revision No: 2

Page 6 of 6